Altimmune (ALT) Competitors

$2.84 +0.03 (+0.89%)

As of 01:10 PM Eastern

ALT vs. ABCL, VIR, IMTX, PGEN, and IMCR

Should you buy Altimmune stock or one of its competitors? MarketBeat compares Altimmune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Altimmune include AbCellera Biologics (ABCL), Vir Biotechnology (VIR), Immatics (IMTX), Precigen (PGEN), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry.

How does Altimmune compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

AbCellera Biologics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market.

AbCellera Biologics has a net margin of -181.75% compared to Altimmune's net margin of -214,860.98%. AbCellera Biologics' return on equity of -14.86% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Altimmune	-214,860.98%	-42.57%	-35.57%

AbCellera Biologics currently has a consensus target price of $7.80, suggesting a potential upside of 49.86%. Altimmune has a consensus target price of $16.67, suggesting a potential upside of 489.97%. Given Altimmune's higher possible upside, analysts plainly believe Altimmune is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Comparatively, 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Altimmune had 9 more articles in the media than AbCellera Biologics. MarketBeat recorded 13 mentions for Altimmune and 4 mentions for AbCellera Biologics. Altimmune's average media sentiment score of 0.43 beat AbCellera Biologics' score of -0.17 indicating that Altimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Altimmune has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	21.16	-$146.41M	-$0.48	N/A
Altimmune	$40K	9,188.31	-$88.09M	-$0.93	N/A

Summary

AbCellera Biologics beats Altimmune on 9 of the 17 factors compared between the two stocks.

How does Altimmune compare to Vir Biotechnology?

Altimmune (NASDAQ:ALT) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Altimmune presently has a consensus price target of $16.67, indicating a potential upside of 489.97%. Vir Biotechnology has a consensus price target of $20.25, indicating a potential upside of 126.51%. Given Altimmune's higher possible upside, equities analysts plainly believe Altimmune is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Altimmune has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Altimmune had 5 more articles in the media than Vir Biotechnology. MarketBeat recorded 13 mentions for Altimmune and 8 mentions for Vir Biotechnology. Altimmune's average media sentiment score of 0.43 beat Vir Biotechnology's score of 0.28 indicating that Altimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Vir Biotechnology has a net margin of -638.88% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

Altimmune has higher earnings, but lower revenue than Vir Biotechnology. Altimmune is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	9,188.31	-$88.09M	-$0.93	N/A
Vir Biotechnology	$64.69M	23.31	-$437.99M	-$3.13	N/A

Summary

Altimmune beats Vir Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Altimmune compare to Immatics?

Immatics (NASDAQ:IMTX) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Altimmune has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	27.08	-$222.26M	-$1.99	N/A
Altimmune	$40K	9,188.31	-$88.09M	-$0.93	N/A

Immatics has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

64.4% of Immatics shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Altimmune had 11 more articles in the media than Immatics. MarketBeat recorded 13 mentions for Altimmune and 2 mentions for Immatics. Altimmune's average media sentiment score of 0.43 beat Immatics' score of 0.00 indicating that Altimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immatics has a net margin of -572.35% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Altimmune	-214,860.98%	-42.57%	-35.57%

Immatics currently has a consensus price target of $19.00, indicating a potential upside of 72.26%. Altimmune has a consensus price target of $16.67, indicating a potential upside of 489.97%. Given Altimmune's higher possible upside, analysts clearly believe Altimmune is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Altimmune beats Immatics on 10 of the 15 factors compared between the two stocks.

How does Altimmune compare to Precigen?

Altimmune (NASDAQ:ALT) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Precigen has a net margin of -646.99% compared to Altimmune's net margin of -214,860.98%. Precigen's return on equity of 717.50% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Precigen	-646.99%	717.50%	58.48%

Altimmune has higher earnings, but lower revenue than Precigen. Precigen is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	9,188.31	-$88.09M	-$0.93	N/A
Precigen	$9.68M	155.24	-$250.64M	-$1.18	N/A

Altimmune has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, Precigen has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Altimmune currently has a consensus target price of $16.67, suggesting a potential upside of 489.97%. Precigen has a consensus target price of $11.00, suggesting a potential upside of 160.97%. Given Altimmune's stronger consensus rating and higher probable upside, equities research analysts plainly believe Altimmune is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Precigen had 5 more articles in the media than Altimmune. MarketBeat recorded 18 mentions for Precigen and 13 mentions for Altimmune. Precigen's average media sentiment score of 0.54 beat Altimmune's score of 0.43 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

78.1% of Altimmune shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 1.6% of Altimmune shares are held by insiders. Comparatively, 47.1% of Precigen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Altimmune and Precigen tied by winning 8 of the 16 factors compared between the two stocks.

How does Altimmune compare to Immunocore?

Altimmune (NASDAQ:ALT) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Immunocore has higher revenue and earnings than Altimmune. Immunocore is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	9,188.31	-$88.09M	-$0.93	N/A
Immunocore	$412.81M	3.63	-$35.51M	-$0.55	N/A

In the previous week, Altimmune had 12 more articles in the media than Immunocore. MarketBeat recorded 13 mentions for Altimmune and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.59 beat Altimmune's score of 0.43 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunocore	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Altimmune has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Altimmune currently has a consensus price target of $16.67, suggesting a potential upside of 489.97%. Immunocore has a consensus price target of $57.75, suggesting a potential upside of 95.23%. Given Altimmune's higher probable upside, analysts plainly believe Altimmune is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Immunocore	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

Immunocore has a net margin of -6.68% compared to Altimmune's net margin of -214,860.98%. Immunocore's return on equity of -7.07% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Immunocore	-6.68%	-7.07%	-2.55%

Summary

Immunocore beats Altimmune on 12 of the 17 factors compared between the two stocks.

Get Altimmune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALT vs. The Competition

Export

Metric	Altimmune	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$367.53M	$3.00B	$6.30B	$12.24B
Dividend Yield	N/A	1.97%	2.80%	5.36%
P/E Ratio	-3.04	17.60	20.78	25.33
Price / Sales	9,188.31	248.00	517.98	71.73
Price / Cash	N/A	56.99	43.18	55.00
Price / Book	1.30	4.54	9.93	6.97
Net Income	-$88.09M	$74.99M	$3.54B	$334.92M
7 Day Performance	-3.25%	-3.68%	-0.37%	-1.12%
1 Month Performance	-17.16%	-5.32%	-0.84%	0.32%
1 Year Performance	-49.46%	34.96%	33.87%	33.28%

Altimmune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALT Altimmune	3.6292 of 5 stars	$2.85 +0.9%	$16.67 +485.8%	-51.8%	$370.13M	$40K	N/A	50	Analyst Forecast Analyst Revision
ABCL AbCellera Biologics	2.7769 of 5 stars	$5.25 +0.2%	$8.17 +55.6%	+118.7%	$1.60B	$75.13M	N/A	500
VIR Vir Biotechnology	2.8753 of 5 stars	$9.29 +1.9%	$20.25 +118.0%	+87.7%	$1.54B	$68.56M	N/A	580
IMTX Immatics	1.913 of 5 stars	$11.54 +1.5%	$19.00 +64.6%	+107.8%	$1.52B	$54.60M	N/A	260	Analyst Forecast
PGEN Precigen	3.8766 of 5 stars	$4.20 -0.2%	$9.50 +126.2%	+202.8%	$1.50B	$9.68M	N/A	190	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALT) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Altimmune (ALT) Competitors

ALT vs. ABCL, VIR, IMTX, PGEN, and IMCR

How does Altimmune compare to AbCellera Biologics?

Summary

How does Altimmune compare to Vir Biotechnology?

Summary

How does Altimmune compare to Immatics?

Summary

How does Altimmune compare to Precigen?

Summary

How does Altimmune compare to Immunocore?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT vs. The Competition

Altimmune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Altimmune (ALT) Competitors

ALT vs. ABCL, VIR, IMTX, PGEN, and IMCR

How does Altimmune compare to AbCellera Biologics?

Which has more risk and volatility, ABCL or ALT?

Is ABCL or ALT more profitable?

Do analysts rate ABCL or ALT?

Do institutionals and insiders have more ownership in ABCL or ALT?

Does the media refer more to ABCL or ALT?

Which has better earnings & valuation, ABCL or ALT?

Summary

How does Altimmune compare to Vir Biotechnology?

Do analysts rate ALT or VIR?

Which has more risk & volatility, ALT or VIR?

Do institutionals & insiders believe in ALT or VIR?

Does the media refer more to ALT or VIR?

Is ALT or VIR more profitable?

Which has preferable earnings & valuation, ALT or VIR?

Summary

How does Altimmune compare to Immatics?

Which has preferable valuation and earnings, IMTX or ALT?

Which has more risk and volatility, IMTX or ALT?

Do insiders and institutionals have more ownership in IMTX or ALT?

Does the media favor IMTX or ALT?

Is IMTX or ALT more profitable?

Do analysts rate IMTX or ALT?

Summary

How does Altimmune compare to Precigen?

Is ALT or PGEN more profitable?

Which has better valuation and earnings, ALT or PGEN?

Which has more volatility & risk, ALT or PGEN?

Do analysts prefer ALT or PGEN?

Does the media refer more to ALT or PGEN?

Do institutionals & insiders have more ownership in ALT or PGEN?

Summary

How does Altimmune compare to Immunocore?

Do insiders & institutionals hold more shares of ALT or IMCR?

Which has preferable earnings and valuation, ALT or IMCR?

Does the media prefer ALT or IMCR?

Which has more risk & volatility, ALT or IMCR?

Do analysts recommend ALT or IMCR?

Is ALT or IMCR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT vs. The Competition

Altimmune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools